Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Core Insights - Jasper Therapeutics is making significant progress in the BEACON and SPOTLIGHT studies for briquilimab, with patient enrollment exceeding expectations and additional dosing cohorts being added [1][2][3] Study Progress - Enrollment in the BEACON study is ongoing, with the 240mg single-dose cohort actively enrolling patients and a new 180mg Q8W cohort expected to open for enrollment soon [1][3] - Initial data from the BEACON study, including results from dosing cohorts up to 240mg, is planned for presentation in the fourth quarter of 2024 [2][3] - The SPOTLIGHT study is also progressing, with ongoing enrollment in the second cohort (120mg) and initial data expected to be reported in the fourth quarter of 2024 [3][4] Financial Performance - As of June 30, 2024, the company reported cash and cash equivalents totaling $106.8 million [5] - Research and development expenses for the second quarter of 2024 were $11.3 million, while general and administrative expenses were $4.7 million [5][11] - The net loss for the quarter was $15.0 million, translating to a net loss per share of $0.97 [5][11] Briquilimab Overview - Briquilimab is a targeted monoclonal antibody that inhibits the c-Kit receptor, aiming to treat mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and asthma [6][7] - The drug has shown a promising safety profile and efficacy in over 145 participants and healthy volunteers across various studies [6][7] Future Developments - The company plans to initiate a Phase 1b/2a study in asthma patients in the fourth quarter of 2024 [4] - Jasper is expanding its mast cell portfolio and has hosted webinars to discuss briquilimab's potential in various indications [3][4]